Skip to main content

AbbVie Inc.

corporate_fare Company Profile

AbbVie Inc.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Exchange: NYSESector: Life Sciences

show_chartPrice Chart

Loading chart...

feed ABBV - Latest Insights

ABBV
Apr 23, 2026, 4:11 PM EDT
Source: Reuters
Importance Score:
8
ABBV
Apr 12, 2026, 11:00 AM EDT
Source: dpa-AFX
Importance Score:
7
ABBV
Apr 08, 2026, 12:17 PM EDT
Source: Reuters
Importance Score:
7
ABBV
Apr 03, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
ABBV
Mar 23, 2026, 4:59 PM EDT
Filing Type: DEF 14A
Importance Score:
7
ABBV
Mar 09, 2026, 4:31 PM EDT
Filing Type: PRE 14A
Importance Score:
7
ABBV
Mar 09, 2026, 8:23 AM EDT
Source: MFN by Modular Finance
Importance Score:
7
ABBV
Mar 04, 2026, 4:59 PM EST
Filing Type: 8-K
Importance Score:
7
ABBV
Mar 02, 2026, 8:32 AM EST
Source: Reuters
Importance Score:
8
ABBV
Feb 26, 2026, 5:07 PM EST
Filing Type: 424B5
Importance Score:
8
ABBV
Feb 24, 2026, 7:47 PM EST
Filing Type: FWP
Importance Score:
8
ABBV
Feb 20, 2026, 2:38 PM EST
Filing Type: 10-K
Importance Score:
9
ABBV
Feb 04, 2026, 7:54 AM EST
Filing Type: 8-K
Importance Score:
8
ABBV
Jan 07, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7